(June 25, 2014) - Paul Hastings, a leading global law firm, announced today that the firm advised CDH Investments (“CDH”), one of the largest alternative asset management institutions in China focusing on investments in private equity, venture capital, real estate, mezzanine and public equity markets, as the Subscriber in the HK$300,000,000 convertible bond issuance by Hong Kong-listed China Grand Pharmaceutical and Healthcare Holdings Limited (“China Grand Pharmaceutical”). China Grand Pharmaceutical and its subsidiaries engage in the research and development, manufacturing and sales of pharmaceutical and healthcare products.
In addition, the firm also advised CDH on the US$25 million acquisition of up to 20% interest in Shanghai Weicon Optical Co. Ltd., a leading contact lens and solutions manufacturer in China. China Grand Pharmaceutical will simultaneously make an acquisition of up to 55% in Shanghai Weicon Optical Co. Ltd.
Paul Hastings has previously advised CDH on a number of its investments, including the HK$850 million convertible bond offering issued by Hong Kong-listed Man Wah Holdings Limited in 2013, and the US$40 million acquisition of a 20% interest in a gold mine in Heilongjiang Province, China, in February 2014.
The Paul Hastings team was led by partners Vivian Lam
and Nan Li
, with support from associates Erika Wan
, Sunny Li
and May Lun
. Paul Hastings is a leading global law firm with a strong presence throughout Asia, Europe, Latin America, and the United States. Through a collaborative approach, entrepreneurial spirit, and commitment to client service, the professionals of Paul Hastings deliver innovative solutions to many of the world’s top financial institutions and Fortune 500 companies.